1.
Mammographic screening: evidence from randomised controlled trials
2.
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer
Pathologic features of prostate cancer found at population-based screening with a four-year interval